Clinical & Scientific

NurExone Biologic reports statistically significant preclinical data for its exosome therapy, taking a crucial step toward reversing optic nerve damage.

New clinical data reveals how dynamic perfusion technology is preventing catastrophic bedsores in critically ill ECMO patients and saving hospitals millions.

Thorne’s latest consumer study claims massive cognitive and physical gains. But what does the data actually say about the mind-muscle connection?

In the race for a 'longevity protein' therapy, a key safety milestone is met. This de-risks the path to the clinic, but what does it mean for the future?

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

Calidi Biotherapeutics' RedTail platform uses a virus to make tumors produce their own medicine, a strategy that could finally defeat solid cancers.

Beyond fixing connectivity on restrictive networks, Surfshark's update to its Dausos protocol reveals a larger ambition: setting a new, quantum-proof standard.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

A new AI tool scores meals on insulin impact, not calories. Can this data-driven approach disrupt the wellness market where others have stalled?

An independent study reveals a Quebec-based platform dramatically improves patient outcomes and slashes clinical workload. Is this the new OS for healthcare?

A startup's audacious plan for a Moon hotel relies not on rockets, but on powerful digital simulations that de-risk humanity's next great leap.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?